The small molecule inhibitor YK-4-279 disrupts mitotic progression of neuroblastoma cells, overcomes drug resistance and synergizes with inhibitors of mitosis

Neuroblastoma is a biologically and clinically heterogeneous pediatric malignancy that includes a high-risk subset for which new therapeutic agents are urgently required. As well as MYCN amplification, activating point mutations of ALK and NRAS are associated with high-risk and relapsing neuroblasto...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Lett
Main Authors: Kollareddy, Madhu, Sherrard, Alice, Park, Ji Hyun, Szemes, Marianna, Gallacher, Kelli, Melegh, Zsombor, Oltean, Sebastian, Michaelis, Martin, Cinatl, Jindrich, Kaidi, Abderrahmane, Malik, Karim
Formato: Artigo
Idioma:Inglês
Publicado: Elsevier Science Ireland 2017
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5542135/
https://ncbi.nlm.nih.gov/pubmed/28602975
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.canlet.2017.05.027
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares